Israel Englander’s Mereo BioPharma MREO Stock Holding History

Israel Englander’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-57,700	Closed	-$119K	–	6297
2025 Q3	$119K	Sell	57,700 -231,000	-80%	-$426K	﹤0.01%	5667
2025 Q2	$782K	Hold	288,700	–	–	﹤0.01%	4594
2025 Q1	$650K	Buy	288,700 +241,000	+505%	+$682K	﹤0.01%	4651
2024 Q4	$167K	Buy	+47,700	New	+$187K	﹤0.01%	5359

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Israel Englander's MREO Position: Q2 2026 in Review

Israel Englander sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 3,559,103 shares — an estimated $1.17M sold.

Israel Englander first reported a position in MREO in Q4 2020 and held it in 22 quarters. The position peaked at $22.2M in Q3 2024. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Israel Englander reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 3,559,103 Mereo BioPharma shares in Q2 2026, an estimated $1.17M.
Israel Englander first reported a position in Mereo BioPharma in Q4 2020 and held it in 22 quarters.
Israel Englander's Mereo BioPharma position peaked at $22.2M in Q3 2024.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.